Valeant Pharmaceuticals International has signed an agreement to sell its manufacturing facilities in Humacao, PR and Basel, Switzerland to Legacy Pharmaceuticals International. The sale includes the company’s Reptilase product. Terms of the transaction were not disclosed.
     
Timothy C. Tyson, Valeant’s president and chief executive officer, said, “The sale of the two manufacturing sites in Basel and Humacao represents the final step in our restructuring initiative, most of which was completed last year. We continue to make excellent progress toward the achievement of our metric goals.”